THU0409 (2020)
A RANDOMIZED, PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ANAKINRA IN DIFFICULT-TO-TREAT ACUTE GOUTY ARTHRITIS: THE ANAGO STUDY
THU0439 (2020)
EFFICACY AND SAFETY OF ANAKINRA IN THE TREATMENT OF RECURRENT GOUT FLARES: RESULTS FROM THE EXTENSION PHASE OF THE ANAGO STUDY

Figure 1: Median patient-assessed pain intensity (VAS) in index joint at each time point over flares

Number of patients for each flare:
- Triamcinolone (Flare 1: 54, Flare 2: 17, Flare 3: 5)
- Total anakinra (Flare 1: 108, Flare 2: 42, Flare 3: 26)
- Anakinra 100 mg/day (Flare 1: 56, Flare 2: 22, Flare 3: 13)
- Anakinra 200 mg/day (Flare 1: 52, Flare 2: 20, Flare 3: 13)
RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE: RESULTS AT 2 YEARS FROM THE SELECT-COMPARE AND SELECT-EARLY STUDIES


Figure 1. Mean Change in mTSS from Baseline in SELECT-COMPARE (A) and SELECT-EARLY (B)

aPer study design, all patients in the PBO group who were not previously rescued were switched to UPA 15 mg at wk 26.

Least squares mean estimator is based on an ANCOVA model with treatment and prior bDMARD (SELECT-COMPARE) or geographic region (SELECT-EARLY) as fixed factors and baseline value as a covariate. Error bars represent 95% confidence interval.
RADIOGRAPHIC OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE: RESULTS AT 2 YEARS FROM THE SELECT-COMPARE AND SELECT-EARLY STUDIES


Figure 2. Proportion of Patients with No Radiographic Progression in SELECT-COMPARE (A) and SELECT-EARLY (B)

Per study design, all patients in the PBO group who were not previously rescued were switched to UPA 15 mg at wk 26.
Figure 1. Cumulative probability of change from baseline to Week 12 in total erosion score (a) and total backfill score (b).